

Authors' correction

"Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease". W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, H. Olsson. *Eur Respir J* 2003; 21: 74–81.

Unfortunately, there was an error in the 12-month, total symptom scores data in table 4. The correct version of table 4 is reproduced below.

Table 4. –Symptom scores for first week of treatment and at 12 months

Treatment comparisons	Total symptom score (0–16)		Awakening score (0–4)		Shortness of breath score (0–4)		Cough score (0–4)		Chest tightness score (0–4)	
	Week 1	12 months	Week 1	12 months	Week 1	12 months	Week 1	12 months	Week 1	12 months
Budesonide/formoterol <i>versus</i> placebo	-1.21 (p<0.001)	-1.12 (p<0.001)	-0.30 (p<0.001)	-0.34 (p<0.001)	-0.35 (p<0.001)	-0.36 (p<0.001)	-0.28 (p<0.001)	-0.19 (p=0.002)	-0.24 (p<0.001)	-0.21 (p<0.001)
Budesonide/formoterol <i>versus</i> budesonide	-0.80 (p<0.001)	-0.84 (p<0.001)	-0.20 (p=0.004)	-0.20 (p=0.003)	-0.28 (p<0.001)	-0.26 (p<0.001)	-0.15 (p=0.022)	-0.22 (p<0.001)	-0.14 (p=0.020)	-0.13 (p=0.043)
Budesonide/formoterol <i>versus</i> formoterol	-0.69 (p<0.001)	-0.41 (p=0.043)	-0.20 (p=0.005)	-0.16 (p=0.019)	-0.13 (p=0.038)	-0.11 (p=0.107)	-0.17 (p=0.012)	-0.08 (p=0.204)	-0.12 (p=0.047)	-0.03 (p=0.678)

Data are presented as score (p-value).